Novartis’ investigational capmatinib granted FDA priority

12th February 2020 Uncategorised 0

If approved, it will become the first therapy to specifically target METex14 mutated advanced lung cancer, a type of lung cancer with a particularly poor prognosis.

More: Novartis’ investigational capmatinib granted FDA priority
Source: News